BeiGene Announces Acceptance of a Supplemental New Drug Application in China for REVLIMID® in Relapsed or Refractory Indolent Lymphoma

    NEXT STORY
    Roche enters licensing agreement with Sarepta Therapeutics to improve the lives of patients living with Duchenne muscular dystrophy
    PREV STORY
    Progenics Pharmaceuticals to Announce and Host a Conference Call to Discuss Top Line Results from Phase 3 CONDOR Trial of PyL™ in Prostate Cancer on Monday, December 23rd
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    GENEDRIVE PARTNERS WITH FIND TO EVALUATE A MOLECULAR DIAGNOSTIC KIT FOR HEPATITIS C VIRUS IN DECENTRALISED SETTINGS

                                ...

    author_avatar
    NASDAQ Market News

    AnaptysBio to Present at J.P. Morgan 37th Annual Healthcare Conference

    SAN DIEGO, Jan. 02, 2019 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage ...

    author_avatar
    NASDAQ Market News

    ContraFect to Present at Two Upcoming Investor Conferences

    YONKERS, N.Y., Aug. 29, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology ...

    author_avatar
    NASDAQ Market News